Ticagrelor

Mechanism of action

Antiplatelet agent.

Reversible P2Y12 receptor antagonists (ADP receptor inhibitor) and hence inhibiting platelet activation and aggregation but is not a prodrug like clopidogrel.

Indications and dose

Side-effects

Bradycardia

Bleeding

Pruritus

Hypersensitivity (allergy, SJS, TEN, Erythema multidorme)

Thrombotic Thrombocytopenic Purpura

Agranulocytosis

Pharmacokinetics

Onset of action:Within 30 minutes

Brand: Brilinta, Brilique

Metabolism: Hepatic first pass using CYP450: 3A4

Half-life of elimination: 8-12 hours

Excretion: Feces 58%, 26% urine

Directions for administration

PO tablet

Medicinal forms

1 tablet = 60, 90 mg

‍

References

1. https://www.sciencedirect.com/topics/neuroscience/ticagrelor#:~:text=The%20onset%20of%20action%20of,of%208%20to%2012%20hours.
2. https://next.amboss.com/us/article/Um0bUg?q=clopidogrel#Zb288dda860ff65493b01ea10fbf1e10c
3. https://online.epocrates.com/drugs/614607/Brilinta/Pharmacology
4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf